Donne Bennett Caces

Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities

Arnon P. Kater, Carolyn Owen, Carol Moreno et al. · NEJM Evidence · 2022 · 226 citations

Medicine, Oncology, Pharmacotherapy +17

Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Carsten Utoft Niemann, Talha Munir, Carol Moreno et al. · The Lancet Oncology · 2023 · 139 citations · Full text

Life Sciences, Hematology, Immunology +7

Hydroxymethylation at Gene Regulatory Regions Directs Stem/Early Progenitor Cell Commitment during Erythropoiesis

Jozef Madžo, Hui Liu, Alexis Rodríguez et al. · Cell Reports · 2014 · 97 citations · Full text

Life Sciences, Cell Biology, Genetics +17

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

Talha Munir, Carol Moreno, Carolyn Owen et al. · Journal of Clinical Oncology · 2023 · 44 citations · Full text

Medicine, Oncology, Pharmacology +17

An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA

Briseis Aschebrook‐Kilfoy, Donne Bennett Caces, Nicholas J. Ollberding et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2013 · 43 citations

Medicine, Hematology, Oncology +17